Copy
Issue 10 - November 2017
Email not displaying correctly? View it in your browser.
Welcome to the November edition of Tablets, a prescribing newsletter produced monthly by the Medicines Management team at Midlands and Lancashire Commissioning Support Unit.

Contents

Formulary Update

Wirral Drug & Therapeutics Panel – November 2017

Recommendations

RED Tolvaptan
Approved for the 3rd line treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone (SIADH) secretion.

RED Bosutinib (as per NICE TA401)
Approved for use in previously treated chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia as per NICE TA401.

RED Blinatumomab (as per NICE TA450)
Approved for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia as per NICE TA450

GREEN Actikerall
Approved for the treatment of actinic keratosis. Further details will be available in the RAG list in due course.

Local News

PCQS – Antibiotic targets

All practices, as part of PCQS, are asked to find ways to support the Antimicrobial Resistance (AMR) agenda and Antimicrobial stewardship.
Prescribers are asked to appropriately use antibiotics and reduce their broadspectrum antibiotics (cephalosporins, quinolones and co-amoxiclav) by 10% or more.
The information below should provide support for prescribers support in achieving these targets.

Ideas to support you to achieve your targets

 
  • 1. Identify an Antimicrobial Steward within your practice
This person will lead on training others and identifying ways in which your practice can improve their antibiotic prescribing. A mentor to support others within the practice, the Antimicrobial Steward will support the AMR agenda and ensure your practice is on track!
  • 2. Antibiotic Action Plans
Has your practice got an antibiotic action plan? Use this to plan any meetings for peer review and to identify work to be undertaken. Ask any trainee doctors to use the topic of antibiotics for research. Actions plans should be reviewed every quarter and submitted to Medicines Management every 6 months.
  • 3. Follow your local Formulary advice
Support prescribers to use local recommendations and strategies to reduce inappropriate antibiotic prescribing. Ensure the latest Wirral Antimicrobial Guidelines are being used by all prescribers.
  • 4. Regular Audit
Medicines Management can import EMIS web audits into your clinical system for you to run on a monthly basis. These reports will look at all antibiotic volume and broadspectrum volume/choice. The results of the audits could be discussed at clinical meetings or be used for peer or self-reflection.
  • 5. EMIS web Protocols
Medicines Management can set up an EMIS web Protocol for prescribers. This can be tailored to suit individual practice needs. The aim of the protocol is to encourage prescribers to consider if a broadspectrum antibiotic is required and provide reasons for choice. Some practices have found this particularly helpful if they have locum GPs working in their practice.
  • 6. Use Prescribing data
Use the BI portal for information regarding antibiotic prescribing.
  • 7. Use TARGET resources
There is so much information available to prescribers on the TARGET website. Choose from patient information leaflets, to audit resources or e-learning. The Treat Your Infection Leaflet can be embedded into your clinical system, supporting you with prescribing decisions and providing excellent information to your patients. Please ask a member of the Medicines Management Team.
  • 8. Patient information materials
Posters and information leaflets should be available in any patient waiting areas. There are a number of useful resources for healthcare professionals and patients including quizzes and crosswords. For further resources please try – Wirral Medicines Management Website, TARGET resources, Public Health England Antibiotic Awareness resources 2017 amongst others.
A subtitled video entitled 'keep antibiotics working' has been added to Envisage. Please click this link to download to display on practice screens.
  • 9. European Antibiotic Awareness Day and World Antibiotic Awareness Week
Use these awareness campaigns to support prescribing in your practice for November 2017. The European Antibiotic Awareness Day is 18th November 2017. World Antibiotic Awareness Week runs from 13th to 19th November 2017.
  • 10. Keep Antibiotics Working Public Campaign
Public Health England (PHE) has launched a new campaign to help tackle antibiotic resistance. Keep Antibiotics Working highlights that taking antibiotics when you do not need them puts you and your family at risk and to always ask your doctor or nurse for advice. Practices should have received their GP surgery packs a couple of weeks ago. If you have not received these packs please contact WICCG.PrimaryCareComms@nhs.net.

The campaign has produced a new animated TV advert and social media, local pharmacies, GP surgeries and local authorities will be supporting it.
  • 11. E-learning
As well as TARGET resources and e-learning, there is also a very useful e-learning programme for medical and non-medical practice staff. Try this as a training option for your next in house PLT.

The prescribing lead GP must undertake and all other GPs should consider the following e-learning for PCQS: TARGET: Antibiotic Resistance in Primary Care
And TARGET: Managing Acute Respiratory Tract Infections
Use this learning to feedback to colleagues and share good practice.
  • 12. Delayed Prescribing
Delayed antibiotic (or back up) prescribing is a proven technique for reducing unnecessary antibiotic prescribing. Prescribers can use this approach when there is clinical uncertainty about whether a condition is self-limiting or is likely to deteriorate. There is a NICE Quality Standard which provides information regarding this technique and about the methods that can be used for evaluation.
A back-up (delayed) prescription is a prescription (which may or may not be post-dated) given to a patient or carer, with the assumption that it will not be dispensed immediately, but in a few days if symptoms worsen. It may also be left at an agreed location (for example, the local pharmacy) to be collected at a later date.

Always use a suitable READ code – such as “Deferred antibiotic therapy” 8BP0.

Remember only use this technique where needed – if you are confident that an antibiotic is not required then do not prescribe. Evidence shows that time taken educating patients that an antibiotic is not required will reduce future consultations.
  • 13. Peer review at Prescribing cluster group
As part of PCQS, prescribers are asked to attend prescribing cluster groups to feedback about any antibiotic work that has been undertaken in their practice. Please use this opportunity to discover what has worked well for others and what techniques haven’t been successful. These ideas could be implemented in your own practice in the future. It is expected that the March 2018 cluster groups will be reserved for this purpose (dates to be arranged).
 
  • 14. Pledge to be an Antibiotic Guardian
Ask all practice staff to pledge to be an Antibiotic Guardian by visiting the antibiotic guardian website.

Submission of PCQS evidence

Evidence for PCQS should be submitted to the Medicines Management Team through the Prescribing Adviser email address - mlcsu.prescribingadviserswirral@nhs.net.
Where possible please send electronic evidence.



Clostridium difficile – Wirral Infection Prevention & Control Service

There were 3 reported cases of community attributed Clostridium difficile infection in October 2017. The key learning points from these reviews were:
Loperamide should not be prescribed when C difficile infection is suspected as a cause for diarrhoea
Areas of good practice identified from the three October reviews were as follows:
 
  • Prompt stool sampling
  • Antibiotics stepped down appropriately and in a timely manner
  • Clinical specimens were obtained
  • Practices liaised with the IPC Service and WUTH Microbiologist

C difficile rates per 100,000 for Wirral continue to be higher than both North West and England:



Fosfomycin (oral) Shared Care Agreement: Reminder

The RAG status of fosfomycin changed from RED to AMBER earlier this year. It is approved for ESBL and CPE UTIs.
There is a UK licensed oral fosfomycin preparation (Monuril 3 g granules for oral solution) for the treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females.
Fosfomycin (oral) is also used to treat uncomplicated UTI in men which is an unlicensed indication. GPs will only be asked to prescribe oral fosfomycin on Medical Microbiologist recommendation. A shared care guideline to support GPs in prescribing is available.

Safety Update

For more information on the updates listed below, please click here:
 
Safety Articles

Professional use HIV test: Alere HIV Combo – risk of false positive results
Central Alerting System | 05 Oct 2017
Specific lots are affected, listed in the manufacturer’s Field Safety Notice.
https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102655

 
HIV Pharmacy Association of the UK advises no interaction between the influenza vaccine and antiretrovirals
HIV Pharmacists Association | 12 Oct 2017
The HIV Pharmacy Association is advising that it is safe to give patients on antiretroviral therapy the influenza vaccine without compromising either the vaccine or the patient’s HIV treatment.
http://www.hivpa.org/information-for-healthcare-professionals/

Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg)
Medicines and Healthcare Regulatory Agency | 26 Oct 2017
Do not use in patients with a known or suspected allergy to cows’ milk.
https://www.gov.uk/drug-safety-update/methylprednisolone-injectable-medicine-containing-lactose-solu-medrone-40-mg-do-not-use-in-patients-with-cows-milk-allergy

Gabapentin (Neurontin) Risk of severe respiratory depression.
Medicines and Healthcare Regulatory Agency | 26 Oct 2017
Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use of central nervous system (CNS) depressants, and elderly people might be at higher risk of experiencing severe respiratory depression.
Medicines and Healthcare Regulatory Agency | 26 Oct 2017
Rare reports of erectile dysfunction and decreased libido.
https://www.gov.uk/drug-safety-update/isotretinoin-roaccutane-rare-reports-of-erectile-dysfunction-and-decreased-libido

Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
Medicines and Healthcare Regulatory Agency | 26 Oct 2017
If constipation occurs during treatment with clozapine (Clozaril, Denzapine, Zaponex), it is vital that it is recognised and actively treated.
Medicines and Healthcare Regulatory Agency | 26 Oct 2017
Do not initiate new patients; transition all current patients to an alternative therapy by July 2018.
Medicines and Healthcare Regulatory Agency | 26 Oct 2017
The audible and/or vibration alarms might not function, which may lead to hyperglycaemia if the user doesn’t see the notification message on the pump.

SPC Updates here

Drug Availability

Products in short supply and product discontinuations
 
The following links provide prescribers with up to date information on commonly prescribed products which are currently in short supply from the manufacturers.
 
The information held on these lists is not exhaustive. Availability can vary geographically and also between wholesalers. Up-to-date information should be sought from manufacturers, local community pharmacies and suppliers.
 
Supply issues
 
Felodipine
 
There are supply issues with felodipine currently. This is expected to be short term, with all strengths expected to be back in stock with the wholesalers within two weeks. 
 
There are no current manufacturing problems with Cardioplen, however due to shortages of the generic product the manufacturer cannot keep up with demand for Cardioplen. They are sending weekly stocks to all wholesalers. Prescribers are advised to prescribe generic felodipine on acute if the pharmacy reports being out of stock rather than switching all patients to generic. Prescriptions should be limited to 28 days’ supply.
 
In some cases, consideration may need to be given to switch patients to another calcium channel blocker such as amlodipine. This should be undertaken on an individual patient basis after assessment of their current blood pressure. Doses available of amlodipine are 5mg and 10mg. Felodipine is available as 2.5mg, 5mg and 10mg. If switching from any dose of felodipine, then it is recommended that 5mg of amlodipine should be initiated and titrated upwards if necessary. Blood pressure should be monitored at least weekly.  It is recommended that patients are monitored regularly when switching between antihypertensive agents.
 
There is insufficient data available about switching from felodipine to amlodipine as referenced in Medicines Q&A entitled “How do amlodipine and felodipine compare for the treatment of hypertension or prophylaxis of stable angina?” 2015, updated 2016.
 
The Wirral Hypertension (primary, uncomplicated) Treatment Guidelines in Adults  can be found at this link: http://mm.wirral.nhs.uk/document_uploads/guidelines/Hypertension-Algorithm-clinical-guideline-V2-FINAL.pdf
 

Messages on ScriptSwitch have been suspended until the shortage has resolved. We will continue to monitor the situation and update you if anything changes.
 

Entresto
 
Some pharmacies have been reporting supply issues with Entresto. The manufacturers have confirmed that there are no manufacturing or supply problems.
If there are any problems with ordering through the usual routes, then Novartis Customer Service have informed us that pharmacies can order direct by calling 0845 741 9442. They have confirmed that with this route of supply there are no hidden charges.

Stanek (levodopa/carbidopa/entacapone) supplies

Teva advise that there will be a severe supply disruption to Stanek, affecting multiple strengths and pack sizes between now and December 2017. Product specific information can be found in the attached DHCP letter from Teva.

The suppliers of the alternative levodopa/ carbidopa/ entacapone supplies about this disruption, who have confirmed the following:

Orion- good supplies of Stalevo remain available for all strengths.

Accord- supplies of Sastravi remain available for all strengths, but they do have some short term issues on some lines but further stock expected in next two weeks.

Sastravi is the Wirral cost effective brand of choice.

Shortage of Pneumococcal polysaccharide vaccine
 
There is a current shortage of the PPV23 vaccine which is likely to continue for the foreseeable future. There is only one licensed vaccine available and although the company are expecting more stock deliveries during October, the volume anticipated is unlikely to be sufficient to vaccinate the whole 65 year old cohort this winter.

After discussion with the BMA's General Practitioners Committee, the attached document has been produced to provide advice for general practices during this time. The main recommendation is that practices plan to deliver the bulk vaccine programme across the year. For those at high risk, it is important to ensure that other preventive measures, including influenza vaccination, are implemented. It is also recommended that the records of such patients are flagged so that they can be called for vaccine once the stock situation improves.
 
There is no shortage of the PCV13 vaccine used in infants and toddlers but this vaccine is not suitable for protection of older people.
 
Trifluoperazine tablets
 
There have been ongoing supply issues affecting trifluoperazine 1mg and 2mg tablets but we have had a recent update to say supplies will not improve until some point in 2018 due to manufacturing issues with the active ingredient.
 
Concordia and Rosemont have trifluoperazine available in liquid formulations and they have good supplies available. 

Glipizide 

We are aware that there is a national shortage of glipizide and this is not due to resolve until January 2018. The following information has been prepared in consultation with the Diabetes team at the Countess of Chester and agreed by WUTH.

Patients should be reviewed on an individual case basis taking into account the following:
• hepatic function
• renal function
• HBA1c/diabetic control
• Age
• hypoglycaemic risk
• other prescribed medication/doses (especially other antidiabetic medication)

This would be a good opportunity to review the appropriateness of a sulphonyurea for each patient. If the decision is made to switch to another sulphonylurea, below are doses that equate approximately to Glipizide 2.5 to 5mg daily:

 
  • Gliclazide 40mg daily
  • Glimepiride 1mg daily

The latest BNF or product SPC should be consulted for details on the dosage regime and the maximum prescribable dose of individual sulphonylureas. Patients would need to monitor blood glucose more frequently (especially at night) and be counselled to recognise signs of hypo and hyperglycaemia.

Discontinued items

Clickstar pen

 
The Clickstar pen is being discontinued but is being replaced by the All-star cartridge pen, so once Clickstar stocks run out then the replacement would be the All-star. 
 
Accolate 20mg Tablets
 
AstraZeneca will be discontinuing Accolate 20mg (zafirlukast) on 31st March 2018. A company communication has been attached. Clinical advice from UKMI has advised montelukast as a likely alternative.

Drug tariff price Changes

 
This summary document shows the top 10 price changes this month, the top 25 changes this quarter, and the top 100 this year. 
Tell me more about drug tariff price changes.

Prescribing News

NICE Guidance - October 2017.

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance that impact upon primary care.
 
The Cystic fibrosis guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
 
The Child maltreatment clinical guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
 
The Sinusitis (acute) antimicrobial prescribing guideline covers the use of antibiotics in sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance.The guideline gives recommendations on managing symptoms, choice of antibiotics and self-care. The visual summary pdf can be accessed here.
 
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

CKS Updates – October 2017

Clinical Knowledge Summaries were reviewed and updated in the following areas;

 
 
The most significant changes are in the Crohn's disease topic where recommendations on the diagnosis and management of confirmed Crohn's disease have been amended in line with current evidence. The Prostate cancer topic has been updated with recommendations on prostate-specific antigen (PSA) testing and treatments for prostate cancer.
 
Action: Clinicians may find the updates useful when reviewing current clinical practice.
 
Please note that the information in this newsletter is correct at the time of publication.
Clinicians should always refer to the most up to date information.


Contacts